What happened
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) were up by a healthy 12.4% on heavy volume as of 11:16 a.m. ET Friday morning. The biotech's stock appears to be getting a boost from both a broad upward trend across the biotechnology space today, as well as from rumors circulating on social media about a possible buyout.
So what
Bluebird has repeatedly been floated as a possible buyout target by investors this year. Three key issues seem to be fueling this speculation:
- Bluebird scored two approvals from the Food and Drug Administration (FDA) earlier this year for its one-and-done gene therapies: Skysona for cerebral adrenoleukodystrophy (CALD) and Zynteglo for transfusion-dependent beta-thalassemia (TDT).
- Bluebird isn't on the soundest of financial footings at the moment. A buyout would thus ensure that these newly approved gene therapies get a proper commercial launch.
- Big pharma has shown a keen interest in buying financially stressed drugmakers with compelling assets all year long. Bluebird, for its part, appears to fit this description to a T.
All that being said, these buyout rumors are not based on any reputable news pieces. Investors, in turn, probably shouldn't put much stock into this speculation.
Now what
Is Bluebird's stock a buy right now? Investors arguably should never buy shares of a biotech purely for its potential as a buyout play. After all, buyouts are exceedingly hard to predict in the biopharmaceutical industry. A buy decision on this stock should thus come down to your view of the company's commercial prospects in CALD and TDT, as well as its ability to financially support a pair of rather unique product launches.
10 stocks we like better than Bluebird Bio
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Bluebird Bio wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 17, 2022
George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Bluebird Bio. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
